Skip to main content

Table 1 Characteristics of the three study groups

From: Pentraxin-3 in non-alcoholic fatty liver disease and its affection by concomitant chronic hepatitis C infection

Parameter

Group Ι

NAFLD patients (n = 25)

Group ΙΙ

NAFLD patients with HCV (n = 25)

Group ΙΙΙ

Healthy control (N = 20)

Mean ± SD

Age (in years)

42.7 ± 11.2

43.3 ± 9.6

42.4 ± 6.9

Body weight (Kg)

94.8 ± 16.8

79.6 ± 10.1

69.7 ± 4.7

Height (cm)

167.7 ± 8.9

171.2 ± 9.8

171.3 ± 3.2

Body mass index (Kg/m2)

33.0 ± 5.1

26.7 ± 2.4

23.7 ± 1.6

Waist circumference (cm)

110.8 ± 15.0

98.8 ± 9.5

83.9 ± 8.0

PCR for HCV (IU/mL)

-

765,324.9 ± 1,510,564.0

-

ALT (U/L)

45.1 ± 20.4

75.4 ± 27.1

13.9 ± 2.1

AST (U/L)

40.6 ± 16.9

52.6 ± 20.4

10.7 ± 1.8

Albumin (g/dL)

4.1 ± 0.2

4.1 ± 0.5

5.5 ± 0.4

Total bilirubin (mg/dL)

0.8 ± 0.2

0.7 ± 0.2

0.3 ± 0.1

Direct bilirubin (mg/dL)

0.3 ± 0.1

0.2 ± 0.1

0.1 ± 0.04

Hemoglobin (g/dL)

13.5 ± 1.2

13.1 ± 1.2

14.4 ± 0.6

 WBC (˟103/cmm)

8.1 ± 1.2

7.2 ± 2.2

8.5 ± 0.8

 PLT (˟103/cmm)

256.5 ± 63.2

226.2 ± 48.6

297.0 ± 20.5

Serum creatinine (mg/dL)

0.8 ± 0.2

0.8 ± 0.2

0.8 ± 0.1

Urea (mg/dL)

19.2 ± 3.1

17.2 ± 2.1

18.5 ± 2.0

Fasting blood sugar (mg/dL)

98.2 ± 48.4

78.1 ± 11.5

70.2 ± 4.6

Post prandial blood sugar (mg/dL)

125.6 ± 44.8

103.3 ± 19.4

92.0 ± 4.2

Triglyceride (mg/dL)

203.2 ± 75.0

161.2 ± 16.2

108.4 ± 10.6

 HDL (mg/dL)

35.4 ± 3.8

33.8 ± 2.4

41.5 ± 6.1

 LDL (mg/dL)

164.7 ± 24.3

146.4 ± 11.1

88.6 ± 7.9

Total Cholesterol (mg/dL)

222.2 ± 30.5

195.6 ± 12.3

157.3 ± 5.7

Plasma PTX3 (ng/mL)

5.5 ± 4.9

5.8 ± 4.5

0.9 ± 0.5

  1. ALT alanine aminotransferase, AST aspartate aminotransferase, HCV hepatitis C virus, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD nonalcoholic fatty liver disease, PTX3 pentraxin-3